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ABSTRACT
The rapidly growing understanding of human
genetic pathways, including those that mediate
cancer biology and drug response, leads to an
increasing need for extensive and reliable mutation
screening on a population or on a single patient
basis. Here we describe s-RT-MELT, a novel
technology that enables highly expanded enzymatic
mutation scanning in human samples for germline
or low-level somatic mutations, or for SNP discov-
ery. GC-clamp-containing PCR products from
interrogated and wild-type samples are hybridized
to generate mismatches at the positions of muta-
tions over one or multiple sequences in-parallel.
Mismatches are converted to double-strand breaks
using a DNA endonuclease (Surveyor
TM) and oligo-
nucleotide tails are enzymatically attached at
the position of mutations. A novel application of
PCR enables selective amplification of mutation-
containing DNA fragments. Subsequently, melting
curve analysis, on conventional or nano-technology
real-time PCR platforms, detects the samples
that contain mutations in a high-throughput and
closed-tube manner. We apply s-RT-MELT in the
screening of p53 and EGFR mutations in cell lines
and clinical samples and demonstrate its advan-
tages for rapid, multiplexed mutation scanning in
cancer and for genetic variation screening in biology
and medicine.
INTRODUCTION
Screening for genetic changes to unveil molecular attri-
butes of human specimens is important for a variety of
medical applications, including genotyping for inherited
disorders, prediction of the pathologic behavior of
malignancies, identiﬁcation of cancer biomarkers and
can aﬀect treatment decisions for individual patients (1–3).
For example, mutations in genes like EGFR can
profoundly inﬂuence chemotherapeutic response in lung
cancer (2–5) and the response is modulated by mutations
in other genes of the same signaling pathway [e.g. K-ras,
HER2, ErbB-3 (1,6)]. Therefore there is a need for eﬃcient
and high-throughput mutation screening of multiple genes
along identiﬁed signal transduction pathways in tumor
samples. Because a large portion of cancer-causing genetic
changes remains unknown and can occur in numerous
positions along tumor suppressor genes (e.g. p53, ATM,
PTEN) mutation scanning rather than detection of speciﬁc
mutations is frequently required for molecular cancer
proﬁling.
Sequencing is often considered the gold standard for
comprehensive mutation analysis. Multi-capillary electro-
phoresis, re-sequencing arrays or pyrosequencing provide
platforms for highly parallel genetic analysis (7–13).
However, the expense associated with these techniques is
currently high both for instrumentation and for running-
costs. Since somatic mutations for most genes are
relatively rare events it can be ineﬃcient to scan for
mutations using expensive approaches that in several cases
provide unnecessary data (14,15). Another issue with
direct sequencing or re-sequencing arrays is the diﬃculty
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presence of a high excess normal alleles, which is
frequently the case with clinical cancer samples (16).
As a less expensive alternative, rapid pre-screening
methods such as SSCP, DGGE, dHPLC, CCM, CDCE
or HR-melting are widely utilized to identify DNA
fragments that contain mutations prior to performing
full sequencing (14,16–20). Enzymatic mutation detection
based on mismatch scanning enzymes like MutY, TDG or
T4 endonuclease VII for mutation pre-screening has also
been employed (21–25), albeit with modest success since
these enzymes cannot detect all possible mutations and
deletions (22) and some of them have substantial activity
on homoduplex DNA (16). Recently an enzymatic
mutation scanning method based on the Surveyor
TM
(CELI/II) nuclease (26,27) combined with dHPLC or gel
electrophoresis detection was introduced that shows
satisfactory selectivity and reliability (1% mutant to
wild-type alleles is detectable) while it also identiﬁes all
base substitutions and small deletions that are important
to cancer (17,28) or to biotechnology and plant genetic
applications [TILLING method (29–34)]. While reliable,
the use of dHPLC for examining Surveyor
TM-generated
DNA fragments is a slow endpoint detection method
restricted to examining a single DNA fragment at a time
and the resulting DNA fragments cannot be sequenced.
This limits analysis of cancer specimens when numerous
samples or genetic regions need to be screened.
We introduce a new approach that enables Surveyor
TM
to scan for mutations over one or several PCR products
simultaneously and selectively amplify and isolate the
mutation-containing DNA fragment(s) via linker-
mediated PCR. By selectively amplifying mutation-
containing DNA from wild-type fragments, the present
approach de-couples enzymatic mutation scanning from
the endpoint detection step. As a result, following
enzymatic action on mismatches any chosen DNA
detection method (real-time PCR, gel/capillary electro-
phoresis, microarray-based detection) can potentially be
used to identify the mutated DNA fragments in a simplex
or multiplex fashion. Here we utilize real-time PCR
coupled with melting curve analysis (Surveyor
TM-
mediated Real Time Melting, s-RT-MELT) to validate
the new technology. We demonstrate that this approach
increases the mutation scanning throughput by 1–2 orders
of magnitude when several (4100) samples are to be
pre-scanned for mutations, enables mutation scanning
over several PCR fragments simultaneously and mutation-
positive samples can be directly sequenced when
somatic mutations are at a low-level ( 1–10% mutant-
to-wild-type ratio) in surgical cancer specimens.
METHODS
Samplesand controls
Genomic DNA from cell lines with deﬁned mutations in
p53 exons, DU145 (exon 6), SW480 (exons 8 and 9),
DLD1 (exon 7) and BT483 (exon 7) was extracted from
cell lines purchased from the American Type Culture
Collection (ATCC), or purchased as puriﬁed DNA when
available. Surgical colon and lung cancer tumor samples
were obtained from the Massachusetts General Hospital
Tumor Bank following Internal Review Board approval.
DNA from the EGFR mutation-positive cell lines A549,
HCC827, H1975 and LU011 and from formalin-ﬁxed-
paraﬃn-embedded lung cancer samples were obtained
from the Lowe Center for Thoracic Oncology, Dana
Farber Cancer Institute following Internal Review Board
approval. We isolated genomic DNA using DNeasy
TM
Tissue Kit (Qiagen).
PCR withprimers containing 50-GC-clamp and 50-M13
Sequences for the 50M13 and GC-clamp portion of the
primers, as well as the gene-speciﬁc portion of the primers
used in this investigation are listed in Supplementary
Table 1. The M13f and GC-clamp sequence was added to
the 50 end of forward and reverse gene-speciﬁc primers
respectively, or vice versa. Twenty microliter PCR reac-
tions were performed from genomic DNA with ﬁnal
concentrations of reagents as follows: 1X JumpStart
TM
buﬀer (Sigma), 0.2mM each dNTP, 0.2mM forward and
reverse primer, 1X JumpStart
TM Taq polymerase (Sigma).
PCR cycling was done on a Perkin Elmer 9600 PCR
machine. The cycling conditions were: 948C, 90s; (948C,
20s/658C, 20s/688C, 1min) 10 cycles, with annealing
temperature decreasing 18C/cycle, touch-down PCR;
(948C, 20s/558C, 20s/688C, 1min) 30 cycles; 688C,
5min. This PCR program was linked to a program for
denaturation and re-annealing of the PCR product
over 10min.
Treatment of cross-hybridized sequenceswith
the Surveyor
TMendonuclease
Five-microliter PCR product (300–500ng) was mixed with
0.5ml Enhancer
TM and 0.5ml Surveyor
TM (Transgenomic)
and incubated at 428C for 20min followed by adding
0.5ml Stop-solution, as per manufacturer’s protocol. The
inactivated Surveyor
TM-digested product was puriﬁed
with PCR QiaQuick
TM puriﬁcation kit (Qiagen) and
eluted in 35ml water. In some experiments, the PCR
product was mixed with an approximately equal amount
of PCR product from wild-type DNA prior to forming
cross-hybridized sequences, to facilitate detection of
homozygous mutations.
Addition ofpolyA-tail on the 30-end
Following puriﬁcation of the Surveyor
TM-treated sample,
Poly-adenine ‘tail’ was added to the 30-ends of DNA
fragments. For each reaction, we added 5ml puriﬁed
surveyor-digested PCR product to a ﬁnal volume of 20ml
with ﬁnal concentration of 1X reaction buﬀer-4, 1X
CoCL2, 0.2mM dATP, 4 U Terminal Transferase
(New England Biolabs). The reaction was incubated at
378C for 10min and inactivated by heating at 758C for
10min.
Real-time PCR, melting curveanalysis and dHPLC
The real-time PCR ampliﬁcation was performed using
Titanium-Taq
TM polymerase (BD-Biosciences - Clontech)
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For each reaction, we added 0.5ml polyA-tailed DNA to a
ﬁnal volume of 20ml with ﬁnal concentration of 1X
Titanium buﬀer, 0.2mM each dNTP, 0.1 LCGreen
(Idaho Technologies), 0.2mM m13f primer, 0.2mM
oligodT-anchor mix GACCACGCGTATCGATGTCG
ACTTTTTTTTTTTTTTTTV
[V represents A, C and G each oligodT-anchor
concentration is 0.067mM, as per RACE protocol (35)],
1 Titanium
TM polymerase (Clontech— BD Biosciences).
The thermocycling program was as following: 1 cycle of
948C for 2min, 25 cycles of 948C for 15s, 558C for 20s
and 688C for 30s for reading ﬂuorescence. Temperature
titration was performed using diﬀerent denaturation
temperatures, 94–828C to experimentally determine con-
ditions that selectively enable mutation-containing frag-
ments to amplify.
The real-time PCR step was immediately followed by
real-time diﬀerential melting curve analysis using the
SmartCycler
TM machine. DNA melting was performed
immediately following PCR on the Smart Cycler I
machine. Samples were heated from 708Ct o9 5 8Ca t
0.18C/s. Diﬀerential ﬂuorescent intensity curves ( dF/dT)
were smoothed and used for identiﬁcation of
melting peak (s).
Altenatively, real-time PCR products were examined
via dHPLC chromatography on a WAVE
TM system
(Transgenomic). Mutation-positive PCR products were
puriﬁed via PCR puriﬁcation kit (Qiagen) and
sequenced using the M13f primer. All experiments were
repeated at least three times in independent runs from
genomic DNA.
Real-timePCRandmeltingusingtheOpenArray
TMplatform
The OpenArray
TM high-throughput, massively parallel
real-time PCR platform (36) (BioTrove) was tested
for compatibility with s-RT-MELT. Forty-eight
samples of p53 exon 8 PCR products were generated
from 48 diﬀerent lung adenocarcinoma samples and
mutation-containing cell lines and processed via
the hybridization and enzymatic steps of s-RT-MELT.
Real-time PCR in the OpenArray
TM platform was
performed with the LightCycler FastStart
TM DNA
Master SYBR Green
TM I (Roche) using 0.2mM M13f
and 0.2mM oligodT-anchor-mix as primers pre-positioned
on the array through-holes (36) and polyA-tailed DNA as
template. The cycling conditions were as follows: 1 cycle at
948C for 2min, 25 cycles of 908C for 15s, 558C for 20s
and 688C for 30s for reading ﬂuorescence using a high
sensitivity imaging camera (36). The real-time PCR step
was immediately followed by real-time diﬀerential melting
curve analysis. Raw data were exported in Excel software
for further analysis. The OpenArray
TM experiment was
repeated twice at the company’s headquarters.
Prediction of melting temperatures
To estimate Tm,min, the PCR denaturation temperature
below which PCR is not eﬃcient it was assumed, as an
initial approximation, that495% hypochromicity must be
present for PCR to work (i.e. any given sequence must be
completely denatured, otherwise it re-forms immediately
when temperature is lowered in the reaction and inhibits
primer binding). The percent melting (hypochromicity)-
versus-temperature relations for GC-clamp-containing
PCR products and Surveyor
TM activity-generated pro-
ducts were estimated using the POLAND algorithm (37),
and the thermodynamic parameters determined by Blake
and Delcourt for 75mM NaCl in the solution (38) were
used. In order to force agreement at a single point,
predicted and observed values for a p53 exon 8 sequence
containing a short GC-clamp were normalized at 888C.
This shift accounts for the inﬂuence on Tm,min of NaCl
and Mg++ content in the reaction, the presence of the
SYBR-GREEN/LC-GREEN dyes and the proprietary
composition of PCR buﬀers. The Tm,min of all other PCR
products was then estimated using these semi-empirically
determined parameters.
RFLP-basedverification of low-level mutation detected
incodon 273,p53 exon 8
The ‘enriched PCR’ method by Behn et al. (39) was used
to sequence codon 273 mutation of p53 exon 8 from
sample CT20 and wild-type samples. In addition, a second
method [Ampliﬁcation via Primer-Ligation At The
Mutation (40,41)] was used to distinguish mutant and
wild-type samples by virtue of the de novo Nla-III site
generated in the mutant sample by the p53 codon
273 G4A mutation.
RESULTS
Overview of thes-RT-MELT assay
The s-RT-MELT assay converts PCR fragments gener-
ated at positions of mutations by the Surveyor
TM enzyme
to fully ampliﬁable sequences that enable selective PCR
ampliﬁcation in a subsequent quantitative PCR detection
method. Following denaturation and re-annealing of PCR
products that leads to formation of cross-hybridized
sequences at the positions of mutations (Figure 1A) the
sample is exposed to Surveyor
TM endonuclease that
recognizes base pair mismatches or small loops with
high speciﬁcity (28) and generates a break on both DNA
strands 30 to the mismatch. The resulting DNA fragments
participate in a terminal transferase (TdT) reaction that
leads to polynucleotide ‘tailing’ (sequential addition of
adenine, poly-A-tail) at the 30-ends. A real-time PCR
reaction is subsequently performed using adjusted condi-
tions that enable selective ampliﬁcation of the mutant-
only fragments, followed by real-time melting curve
analysis for identiﬁcation of mutations in the presence of
SYBR-GREEN
TM or LC-GREEN
TM DNA dye.
To enable selective ampliﬁcation of the mutation-
containing fragments in the real-time PCR step, modiﬁed
primers are employed for the original ampliﬁcation from
genomic DNA (Figure 1B). The forward primer contains a
region speciﬁc to the target gene and a high melting
domain (GC-clamp), while the reverse primer contains a
region speciﬁc to the target gene and an M13 tail (or vice
versa). Following the TdT tailing reaction, the M13 primer
is used for real-time PCR in conjunction with a primer
PAGE 3 OF 11 Nucleic Acids Research, 2007, Vol. 35, No. 12 e84that binds to the poly-A tail. The denaturation tempera-
ture of the real-time PCR reaction is lowered to enable
PCR ampliﬁcation only for fragments that do not
contain GC-clamps. Because the PCR products that
escape digestion by Surveyor
TM contain GC-clamps
(Figure 1B), these fragments do not amplify eﬃciently
during PCR, thereby enabling selective ampliﬁcation of
Surveyor
TM-selected fragments, i.e. an eﬀective ‘puriﬁca-
tion’ of mutation-containing fragments. The subsequent
closed-tube melting curve analysis enables clear separation
of true mutant sequences from PCR dimers or other
artifacts.
Because s-RT-MELT does not require size-separation
for identiﬁcation of enzymatically generated fragments,
more than one sequence can be scanned in parallel
for unknown mutations in a single-tube reaction of
Surveyor
TM. This simple procedure enables the speciﬁcity
of the Surveyor
TM enzyme to be combined with the
throughput and convenience of real-time PCR for rapid
mutation scanning. Finally, because the ampliﬁed mutated
sequences contain deﬁned primers at their ends, direct
sequencing of enzymatically selected PCR products is
readily possible following the real-time melting step,
enabling sequencing of low-level mutations identiﬁed by
Surveyor
TM.
Detection ofp53 exon 8mutations using s-RT-MELT
To provide initial proof of principle for unknown
mutation scanning using s-RT-MELT we utilized cell
lines and tumor samples containing sequencing-identiﬁed
mutations at several positions of p53 exon 8. Figure 2A
depicts dHPLC chromatograms of the products obtained
using a sample containing a p53 exon 8 G4A mutation or
a wild-type sample. The standard Surveyor
TM-dHPLC
approach (28) was ﬁrst employed to identify the mutation
following PCR ampliﬁcation of exon 8 from genomic
DNA. The resulting dHPLC traces contain a single
product for the wild-type and two products for the
mutation-containing sequences (Figure 2A, curves 1 and
2, respectively). Next, s-RT-MELT was used to screen the
same p53 exon 8 sequence. Following PCR ampliﬁcation
Simplex or Multiplex PCR
amplification of one or more exons
A B
PCR PRODUCT(s)
GC-CLAMP
M13
Self-hybridize or cross-hybridize
with wild type DNA: generate
mismatches at positions of mutations
in one or more PCR fragments
Scan for mismatches all fragments
simultaneously using CEL I /SurveyorTM
enzyme.
CEL I /SurveyorTM enzyme.
Use TdT enzyme to add oligonucleotide tail (e.g. oligo-dA)
to 3′OH ends, to serve as primer anchor
GC-CLAMP
GC-CLAMP
M13 M13
Un-digested fragments
Digested fragments
TdT tailing of 3′ DNA ends
Amplify only mutated fragment(s)
coupled w. real time melting
analysis (see B)
3′OH-AA….AA
M13
3′OH-AA…. AA
GC-CLAMP
M13
Perform real time PCR at reduced denaturation temperature to inhibit amplification of
GC-clamp-containing DNA fragments and to selectively amplify only the mutant fragment (s).
Detect mutations via closed tube, high-throughput melting curve analysis.
IF positive, sequence the
amplified mutated DNA fragment
Figure 1. s-RT-MELT for rapid mutation scanning using enzymatic selection and real-time DNA-melting. (A) General outline of the approach.
The dotted line contains the new steps involved in s-RT-MELT relative to previous approaches, i.e. the addition of a 30-polynucleotide tail followed
by real-time PCR that enables selective ampliﬁcation of the Surveyor
TM-cut sequences and real time melting curve analysis. (B) Detailed outline of
the procedure used to selectively amplify the mutation-containing fragments in s-RT-MELT.
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products and exposed them to Surveyor
TM and TdT
tailing. The subsequent real-time PCR was run at diﬀerent
denaturation temperatures and the products were exam-
ined either via dHPLC or via real-time melting-curve
analysis. At the standard denaturation temperature
of 948C the mutation-containing sample contains two
peaks, corresponding to the anticipated ampliﬁcation of
both Surveyor
TM-digested and un-digested fragments
(Figure 2A, curve 3). However, when the PCR denatura-
tion temperature is lowered (e.g. 86–888C) a single PCR
product is generated for the mutant sample, while the
wild-type sample demonstrates no product (Figure 2A,
curves 4–7). In Figure 2B, real-time diﬀerential melting
curves for the PCR reaction run at 888C are depicted. A
peak corresponding to the PCR product from the mutant
sample is again clearly evident, which is absent in the wild-
type sample. Finally, Figure 2C depicts sequencing of the
s-RT-MELT-generated PCR fragment, as well as the
direct sequencing from genomic DNA. The G4A
mutation is evident in both samples. In the s-RT-MELT
product the anticipated addition of the poly-A tail at the
30-position next to the mutation is illustrated.
To examine the selectivity of s-RT-MELT, dilutions of
mutant to wild-type DNA were performed using DNA
from SW-480 cells that harbor a p53 exon 8 14487G4A
homozygous mutation. The real-time PCR reaction was
again performed at 888C and mutant-to wild-type ratios of
 1–10% were distinguished from the wild-type using
either dHPLC (Figure 2D) or melting curve analysis
(Figure 2E). In these samples, direct di-deoxy-sequencing
could not identify a mutation if the ratio of mutant-to-
wild-type was5 30–40% (data not shown). On the other
hand, sequencing of s-RT-MELT products was possible
including the lower dilutions (Figure 2F). sRT-MELT
sequencing generated traces with poly-A tails depicting the
presence and the position of the mutation, although the
exact nucleotide change was less clear than the one in exon
5 (i.e. the position  1 base from the mutation might also
be confused to be a mutation). The reason for this  1 base
ambiguity of the exact position of the mutation can be
probably understood. The PCR performed following
poly-A tail addition contains an equimolar mixture of
three reverse primers (30 ending in V=G, A or C).
Depending on the exact nucleotide at the mutation, the
correct primer should in theory be preferred, while the
other two primers should not allow eﬃcient polymerase
extension due to the mismatched 30-end. However, in
practice this ‘allele-speciﬁc PCR’ step occasionally allows
30-mismatched primer extension, enabling more than one
version of the primer to amplify over the position of the
mutation, or alternatively the incorporation of the poly-A
tail may occur  1 base from the exact position of the
mutation. We conclude that in certain cases sRT-MELT
indicates the position of the mutation to within 1 base,
while in others (e.g. p53 exon 5) it indicates the position
‘and’ the actual nucleotide change.
Next, p53 exon 8 was ampliﬁed using DNA from a
group of 48 surgical lung adenocarcinoma samples and
s-RT-MELT was used for the screening of unknown
mutations via melting curve analysis. Mutations at
diﬀerent positions along exon 8 were present in several
of these clinical samples, as indicated by the shift in
melting proﬁles obtained (Figure 2H) and subsequently
veriﬁed via sequencing. In this set of samples, sRT-
MELT-sequencing detected a low-level mutation on a
colon cancer specimen (CT20) that direct sequencing
failed to identify (Figure 2I). As with Figure 2F, sequenc-
ing of sample CT20 indicated the position of poly-A tail
addition to within one base, but the actual nucleotide
change was diﬃcult to identify. To exclude the possibility
for a false positive, two independent RFLP-based
methods were used to verify the presence of the mutation.
Thus, since the position of poly-A tail addition was known
(Figure 2I, codon 273 of p53 exon 8) the mismatched
primer approach by Behn et al. (42) was used to introduce
an MluI restriction site for the wild-type p53 sample but
not for the codon 273 mutants. Subsequent restriction
with MluI enzyme followed by PCR generated a product
with a 14487G4A mutation for the CT20 sample but
not for the wild-type sample (Supplementary Figure 1,
Frame A). As an additional veriﬁcation for the low-level
CT20 mutation, we observed that G4A mutation
generates a de-novo Nla-III site at the position of the
mutation. Accordingly, we applied ‘Ampliﬁcation via
Primer-Ligation At The Mutation’, a method that we
described previously (40,41) to ligate a primer at the Nla-
III-digested site, and preferentially ampliﬁed the mutant
fragment in a second PCR. The sequenced PCR product
identiﬁed again the 14487G4A mutation (Supplementary
Figure 1, Frame B). In conclusion, sRT-MELT identiﬁed
correctly a p53 codon 273 low-level mutation on CT20
that was missed by regular sequencing. This is very
signiﬁcant as p53 exon 8 mutations at codon 273 have
been associated with bad prognosis in cancer (43,44).
Table 2 of Supplementary Data depicts a good
agreement between standard Surveyor screening, s-RT-
MELT screening and di-deoxy-sequencing, except for the
low-level mutation discovered on sample CT20 via s-RT-
MELT. s-RT-MELT-sequencing traces for two samples
with p53 exons 6 and 7 mutations are also depicted.
The data in Figures 2A–D and H indicate a lack of
substantial PCR ampliﬁcation at denaturation tempera-
tures 4888C for fragments containing the GC-clamp and
a selective ampliﬁcation of the mutation-containing
fragments for several diﬀerent mutation positions on p53
exon 8. To estimate the inﬂuence of the GC-clamp length
on PCR eﬃciency versus temperature and the PCR
ampliﬁcation of fragments generated for mutations lying
at diﬀerent positions along the sequence, a calculation
based on the POLAND algorithm (37) was performed.
The predicted minimum temperatures for substantial PCR
ampliﬁcation were then plotted versus the experimentally
observed values. Three possibilities were simulated, no
GC-clamp, 26 nucleotides (nt) GC-clamp and 117-nt
GC-clamp. DNA fragments corresponding to mutations
at several positions along exon 8 were also simulated and
compared to the experimentally observed minimum
temperatures for generating a PCR product for three
samples that contained mutations at diﬀerent positions
along p53 exon 8 (SW480, CT5 and TL50). The results
(Figure 2G) indicate agreement to within  1.08C between
e84 Nucleic Acids Research, 2007, Vol. 35, No. 12 PAGE6 OF11theoretical prediction and experimental observation. For
denaturation temperatures in the region 85–888Ci n
combination with a 26-nt GC-clamp all the available
mutations on p53 exon 8 are predicted to result in selective
ampliﬁcation of the mutation-containing fragment and
inhibition of the GC-clamp-containing fragment. This
prediction is consistent with the experimental results
obtained from PCR temperature-titration experiments
(Figure 2G). The developed calculation algorithm can
thus be used to predict the appropriate PCR denaturation
temperature for additional PCR fragment/GC-clamp
combinations.
Detection ofp53 exons 5–9mutations and EGFR mutations
in clinical samples
As a further validation for s-RT-MELT, we utilized the
method to identify mutations in additional p53 exons.
Figure 3A depicts the chromatographs obtained when a
1:1 mixture of DNA from SW-480 cells (homozygous
mutation at p53 14686 C4T exon 9) and from wild-type
cells was screened. The real-time PCR reaction was
performed at diﬀerent denaturation temperatures and
the products were examined both via dHPLC and via
melting curve analysis for comparison. As also observed
for p53 exon 8, at 948C denaturation temperature both the
Surveyor
TM-digested and the undigested PCR products
are ampliﬁed during real-time PCR (Figure 3A, curves 1
and 2, mutant and wild-type, respectively). By lowering
denaturation temperature to 858Co r8 4 8C, a single PCR
product is obtained from the mutant while no product,
other than primer dimer, is obtained by the wild-type
sample (Figure 3A, curves 3–6). Figure 3B depicts the
melting curves obtained following real-time PCR at 858C
denaturation temperature for the mutant and wild-type
samples. s-RT-MELT was subsequently applied in the
same manner to screen for p53 mutations in exons 5–7
from cell lines and surgical colon samples harboring
sequencing-identiﬁed mutations including a single-base
frameshift mutation in exon 7 (listed in Supplementary
Table 2). The melting curves from mutant and wild-type
samples in p53 exons 5–7 are depicted in Figure 3C–E.
The data indicate that results similar to those obtained for
p53 exon 8 are also obtained for p53 exons 5, 6, 7 and 9.
Detection of mutations in EGFR exons 18–21 is of
particular clinical interest as these alterations can mod-
ulate response to EGFR inhibitors in lung adenocarci-
noma patients (2,3). Figures 3F, G and H depict the
application of s-RT-MELT for screening DNA from lung
cancer cell lines that harbor dHPLC-identiﬁed alterations
in EGFR exons 19–21, including a two-codon deletion
(del L747-E749, exon 19). The ability of s-RT-MELT for
detecting low-level EGFR mutations was evaluated by
performing DNA dilutions of a heterozygous EGFR exon
20 into a homozygous sample. A 1–10% mutant-to-wild-
type ratio was detectable in this dilution experiment
(Figure 3F). Finally, the application of s-RT-MELT in
detecting mutations in DNA from formalin-ﬁxed paraﬃn-
embedded (FFPE) samples was examined by screening
four clinical FFPE lung adenocarcinoma specimens.
Two of these samples were known to harbor EGFR
exon 21 mutations (L858R), while the other two were
negative for mutations when independently evaluated via
dHPLC (28). Figure 3I demonstrates the identiﬁcation of
the mutational status of these samples via s-PCR-MELT.
Multiplex s-RT-MELT orOpenArray
TM-based
s-RT-MELT increases thethroughput of mutation scanning
A signiﬁcant potential advantage of enzymatic mutation
scanning is the ability to screen several sequences
simultaneously for mutations. To demonstrate that
s-RT-MELT can be used for parallel scanning of
mutations in several PCR products, we mixed equimolar
amounts of PCR products from p53 exons 5–9 containing
mutations either in exon 8 or in exon 9. We then formed
‘cross-hybridized sequences’ and screened the mixture for
mutations in p53 exons 5–9 in a single tube using s-RT-
MELT, as depicted in Figure 1A. Following real-time
PCR and melting curve analysis, the exon 8 or exon 9
mutants were clearly distinguished from the wild-type
sample (Figure 4A, curves 1–3). Next, the mutant exon 8
DNA sample was ﬁrst diluted 10-fold into wild-type
exon 8 and the equimolar mixture of p53 exons 5–9 was
prepared and screened again in a single tube via s-RT-
MELT. The exon 8 mutation was again distinguished
from the wild-type mixture of exons (Figure 4B, curves
1–3). Since480% of p53 mutations in human tumors are
encountered in exons 5–9 (45), the multiplex single-tube
s-RT-MELT reaction could be used to identify most p53
mutations encountered in clinical tumor samples.
Combined with multiplex PCR directly from genomic
DNA, this approach could result to a convenient,
high-throughput method for mutation scanning.
By adopting a real-time PCR platform as endpoint
detection for s-RT-MELT, the throughput for mutation
scanning increases drastically over other mutation pre-
screening approaches that utilize dHPLC, or capillary and
gel electrophoresis. To demonstrate better this point, a
highly parallel nano-technology platform was adopted for
the real-time PCR step of s-RT-MELT that enables an
array of 3072nl volume real-time PCR reactions
(OpenArray
TM system) to be carried-out simultaneously
followed by diﬀerential melting curve analysis (36). As a
proof of principle of the compatibility of s-RT-MELT
with OpenArray
TM, p53 exon 8 PCR products were
generated from 48 diﬀerent lung adenocarcinoma samples
and mutation-containing cell lines and processed via the
hybridization and enzymatic steps of s-RT-MELT. The 48
samples were each dispensed in 10 replicate nano-liter
volume reactions on OpenArray
TM plates pre-fabricated
to contain the appropriate primers and ampliﬁed in 3072
real-time PCR reactions using a denaturation temperature
of 908C in the presence of SYBR-GREEN I dye.
Melting curves were subsequently obtained using the
OpenArray
TM melting curve analysis mode. The PCR
growth curves and smoothed diﬀerential melting curves
obtained distinguish clearly the mutation-containing
samples from wild-type samples (Figure 4C and D,
representative results from 3072 reactions). Furthermore,
identiﬁcation of mutation-containing samples is in
good agreement between the conventional and the
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These data indicate that s-RT-MELT is compatible with
high-throughput nano-technology detection formats and
reiterates the advantage of de-coupling enzymatic selec-
tion from the detection step. Comparison of the through-
put using conventional pre-screening method (dHPLC or
dHPLC/Surveyor
TM) to s-RT-MELT (Table 1) indicates
that s-RT-MELT is 1–2 orders of magnitude faster when a
large number of samples (4100) are screened for muta-
tions. If the multiplex s-RT-MELT format is adopted, the
throughput can increase further.
DISCUSSION
The intrinsic potential of enzymatic mutation scanning for
parallel identiﬁcation of mutations can, in principle, be
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Figure 4. Multiplex s-RT-MELT or OpenArray
TM-based s-RT-MELT. (A) Melting curves obtained following multiplex s-RT-MELT for mixture
of p53 exons 5–9 (exon 8 mutation, curve 2) or exon 9 mutation (curve 3) or wild-type (curve 1). (B) Melting curves obtained following multiplex
s-RT-MELT for mixture of p53 exons 5–9 (exon 8 mutation, curve 3) or 10-fold diluted into wild-type exon 8 mutation (curve 2) and wild-type
(curve 1). (C) OpenArray
TM based s-RT-MELT PCR growth curves for p53 exon 8 using DNA from lung and colon surgical specimens and cell
lines. (D). Melting curves obtained following OpenArray
TM based s-RT-MELT of p53 exon 8 using DNA from lung and colon surgical specimens
and cell lines.
Table 1. Comparison of throughput in mutation scanning
a. Plus the ability to sequence and identify low-level somatic mutations
One sample 16 samples
(e.g. Cepheid
QRT-PCR
machine)
96 samples
(96-well
QRT-PCR
machine)
384 samples
(ABI QRT-PCR
machine)
3,072 samples
(OpenArray
TM)
Detects
low-level
mutations
(1–10%
mutant-to-wild
type)
Nucleotide change
and/or position
of the mutation
dHPLC/Surveyor
b 0.5h 3-4h 24h 96h 768h Yes No
s-RT-MELT
c 1.5h 2.0h 3.0h 4.0h 17h Yes Yes
aPost-PCR treatment time to accomplish pre-screening for unknown mutations.
bSurveyor
TM treatment requires  15–20 minutes. The dHPLC screens one sample at a time (12-15 minutes/sample including wash).
cAn additional half hour for every batch of 96 samples puriﬁed via 96-sample Qiagen puriﬁcation kit, following Surveyor
TM treatment,
was accounted for s-RT-MELT.
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mismatch-containing sequences on a molecule-to-
molecule basis thus providing highly parallel mutation
scanning. However, in the past the selectivity of the
enzymes used and the endpoint detection method has
limited the realization of this potential. Here we enabled
Surveyor
TM, an endonuclease that recognizes selectively
mismatches formed by mutations and small deletions
following ‘cross-hybridized sequence’ formation, to
generate mutation-speciﬁc DNA fragments that are
ampliﬁed and screened via diﬀerential melting curve
analysis. The replacement of size-separation methods
(capillary/gel electrophoresis, dHPLC) by real-time PCR
technology as the endpoint detection platforms and the
ability to scan more than one sequences in parallel result
in a highly increased throughput for s-RT-MELT while
retaining the ability to detect diverse mutations at
low-levels.
Cel I/II endonucleases have also been known to have
exonuclease activity on 50 DNA-ends (26,27). For this
reason, s-RT-MELT was designed to attach an oligonu-
cleotide linker to the 30-DNA ends via terminal transferase
(TdT) instead of using the 50-DNA ends. The exonuclease
activity also tends to degrade the attached 50-GC-clamps
in s-RT-MELT, thereby eliminating their inﬂuence in
reducing ampliﬁcation of un-digested fragments. We
found that if exposure of DNA ‘cross-hybridized
sequences’ to Surveyor
TM is limited to 15–20min, the
substantial degradation of 50-GC-clamps is avoided.
For multiplexing mutation detection using several PCR
products simultaneously, the size of the GC-clamp on
each PCR amplicon may need to be individually adjusted
to ensure that mutations along all sequence positions of
the PCR products included in the mixture can be screened
at a single real-time PCR temperature and that undigested
fragments do not amplify. The calculational tools devel-
oped in this work can be used to guide the individual
design of GC-clamps. s-RT-MELT detects heterozygous
SNPs as well as mutations. As with other mutation pre-
screening techniques, the presence of a SNP concurrently
with a mutation might be diﬃcult to identify without
performing sequencing. Because SNPs occur at ﬁxed
positions, melting peaks originating from SNPs have a
reproducible pattern and melting temperatures (46,47)
thus in many cases they should be distinguishable from
mutations. Finally, it is noteworthy that s-RT-MELT is a
general methodology that may also be applied to isolate
mutations using mismatch-cutting enzymes other than
Surveyor
TM when enzymes with satisfactory properties for
mutation detection become available. Detection platforms
other than real-time PCR/melting (e.g. DNA microarray-
based) may also be envisioned following enzymatic
mutation selection.
In summary, we developed a new method for rapid
mutation scanning, s-RT-MELT that utilizes the Cel I/II
(Surveyor
TM) and terminal deoxy-nucleotide transferase
(TdT) enzymes to isolate and amplify mutation-containing
DNA fragments without the requirement of DNA size-
dependent techniques. Besides enabling highly increased
throughput, multiplexed mutation screening and direct
sequencing of the identiﬁed mutant DNA fragments,
s-RT-MELT also retains the advantages of the Surveyor
endonuclease over alternative pre-screening methods, such
as reliability and identiﬁcation of genetic alterations
present at low (1–10%) fractions in the sample. s-RT-
MELT provides a signiﬁcant advancement in unknown
mutation scanning in cancer research and diagnostics as
well as for general medical, biological and biotechnology
applications.
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